Medical Devices

Carestream Health Unveils New X-ray Detectors, Enhanced X-ray Rooms at World’s Largest Radiology Exhibition

Carestream Health

Carestream’s legacy of delivering quality medical imaging technology continues with the launch of new digital X-ray detectors that help improve clinical outcomes, while enhancements to its existing product portfolio reflect the company’s deep understanding of the radiology profession.

At the annual meeting of the Radiological Society of North America (RSNA) in Chicago, the company is displaying its expanding portfolio of medical imaging systems that provide quantifiable benefits to healthcare organizations and their patients, including

 

  • New Carestream Focus HD 35 and Focus HD 43 detectors that offer higher resolution with a 100 micron pixel pitch that allows for image magnification for better visibility of small objects and microstructures. The detectors’ Cesium (CsI) scintillator is ideal for dose-sensitive pediatric patients; and the detectors have an IP56 rating for better protection against dust and fluid ingress.
  • Next generation of long-length imaging, the Carestream DRX-LC Detector (INVESTIGATIONAL – NOT AVAILABLE FOR COMMERCIAL SALE) captures long-bone and spine images with a single exposure, making it ideal for pediatric imaging and long-bone and spine images of people with limited mobility. In contrast, the traditional multi-shot approach requires three to five exposures followed by manipulation and stitching of the images. The new detector is designed to capture the full image in a single exposure to minimize dose and mitigate motion artifact that can appear from patient movement with a multi-shot exam. The DRX-LC Detector is designed with X-Factor so the detector can be shared across different Carestream X-ray systems and is compatible with both rooms and mobile units.
  • Enhancements to the Carestream DRX-Evolution Plus that provide improved patient comfort and a better ergonomic experience along with improved workflow for the radiographer. Its new tabletop design eliminates rails that can cause strain and discomfort for both radiographer and patient, enabling patients to be moved more smoothly and with less effort to the exam table.
  • New features in the Carestream DRX-Excel Plus provide a better staff experience with faster workflow and better diagnostic image quality. Designed specifically for large and mid-size hospitals and medical centers, this innovative system combines fluoroscopy and general radiology capabilities in one compact unit. It delivers accelerated workflow, high-resolution images and a wide range of patient exam options.

 

Our commitment to quickly respond to the needs of the radiology community with ideas that clearly work is as strong as ever, and we are solidly positioned to continue developing solutions that have quantifiable benefits to our customers and their patients. Organizations can have complete confidence in our ability to provide high-value technology that helps lower costs, and improves imaging workflow for radiology departments, technologists and other healthcare professionals—all with the goal of improving patient care.”

David C. Westgate, Chairman, President and CEO of Carestream

About Carestream Health
Carestream is a worldwide provider of medical imaging systems; X-ray imaging systems for non-destructive testing; and precision contract coating services for a wide range of industrial, medical, electronic and other applications—all backed by a global service and support network.

Spotlight

Spotlight

Related News

Healthcare Analytics

Aya Healthcare Expands into UK with ID Medical Acquisition

Aya Healthcare | January 17, 2024

Aya Healthcare, the largest healthcare talent software and staffing company in the United States, today announced the acquisition of ID Medical, a leading workforce solutions provider in the United Kingdom (U.K.). ID Medical brings over 20 years of experience providing the National Health Service (NHS) and other healthcare organizations with innovative workforce solutions, including workforce management, international recruitment and temporary healthcare staffing. As part of the acquisition, ID Medical will make Aya Healthcare’s market-leading technology available to the NHS and U.K.-based clinicians. The companies plan to share best practices from each market with their respective clients. “We are excited about ID Medical joining the Aya family of brands. We believe that we will deliver enhanced value to our respective clients and clinicians through this cross-Atlantic collaboration,” said Alan Braynin, president and CEO of Aya Healthcare. ID Medical will continue to operate as its own brand in the U.K., supporting thousands of healthcare professionals and hundreds of healthcare organizations. “We are excited to join Aya in our shared mission to transform the healthcare industry worldwide,” said Deenu Patel, CEO of ID Medical. “With Aya’s support, we’ll have access to additional resources, technology and expertise to enhance our services and expand our impact.” About Aya Healthcare Aya Healthcare is the largest healthcare talent software and staffing company in the United States. Aya operates the world’s largest digital staffing platform delivering every component of healthcare-focused labor services, including travel nursing and allied health, per diem, permanent staff hiring, interim leadership, locum tenens and non-clinical professionals. Aya’s software suite, which includes vendor management, float pool technology, provider services and predictive analytics, provides hospital systems greater efficiencies, superior operating results and reduced labor costs. While technology drives efficiency and scale, Aya’s 7,000+ global employees power the company to deliver unparalleled accountability and exceptional experiences for clients and clinicians. Aya’s company culture is rooted in giving back and supports organizations around food security, education, healthcare, safe shelter and equity.

Read More

Health Technology, AI

Swoop Launches AI-Powered Conversational Agent for Healthcare Marketing, Revolutionizing Engagement on brand.com

Swoop | January 09, 2024

Swoop, a leader in developing precise direct to consumer (DTC) and healthcare provider (HCP) audiences for pharmaceutical and life sciences brands, today announced the launch of its AI-powered conversational agent. This groundbreaking advancement in healthcare marketing sets a new standard for lower funnel engagement, enabling immediate, MLR-compliant virtual customer interactions via brand.com. “Swoop’s AI-powered conversational agent marks the first groundbreaking advancement for brand.com since the introduction of pharmaceutical websites in the 1990s, addressing a pressing need for innovation in how the industry engages with their customers,” said Scott Rines, underscoring the historic significance of this achievement. “Patients and physicians are looking for real-time information, 24/7/365 during their moment of need, but are often faced with an overwhelming experience on brand.com. They come to the site seeking fast, clear answers to their health-related questions – our agent solves this.” Market conditions continue to remain a challenge with shortages of healthcare professionals despite an uptick in customer demand for information related to their condition and treatment decisions. Meanwhile, HCPs are also less likely to allow medical reps into their offices, a shift that has continued post-Covid. Instead, these increasingly digital-native, often over-extended, physicians prefer to seek information online when their schedule permits, limiting the impact of personal promotion. “The ability to parse the data derived from lower funnel conversations with HCPs and patients in real time will prove invaluable, as these signals will become proprietary 1st party data to optimize future marketing spend and messaging,” added Rines. Key Features of Swoop's Conversational Agent Dynamic Patient Conversations: Patients and HCPs can engage with conversational AI in real-time, creating a personalized and responsive user experience to drive more high-value actions on a health brand website. MLR-Approved Medical Information: Leveraging advanced algorithms, conversational AI provides MLR-approved answers to both simple and complex medical questions in the moment of need, enhancing the overall user experience for both patients and HCPs. Real-Time Patient Insights: Valuable real-time data from conversations accessible via dashboards allows healthcare brands to assess the effectiveness of their messaging and make informed adjustments promptly. Scalable to Client Demands: Whether for a single brand, therapeutic area or product portfolio, Swoop conversational AI agents can scale with the needs of healthcare marketers from new product launches to covering open territories and unsupported brands. Patient Data Security and Compliance: Swoop prioritizes patient privacy and data security, ensuring that all conversational AI agents operate in compliance with the highest industry standards and regulations. Typical Client Results Seen by Customers 96% – Average answer success rate of inquiries 5.2 minutes – Typical conversation duration 4.7/5 – Average user satisfaction rating 800% – Increase in high-value activities on brand websites Swoop’s conversational AI technology is built on more than 1.3 billion conversations with patients and providers and has been trained under the supervision of physicians and medically trained clinicians. Unlike generative AI, which can hallucinate and is not appropriate for direct patient and HCP interaction in the heavily regulated pharmaceutical industry, Swoop conversational AI uses fine-tuned large language models to understand user intent and surface the most relevant MLR-approved answers to ensure compliance, accuracy and, most importantly, safety. About Swoop Swoop, part of Real Chemistry, enables pharmaceutical and life sciences brands to reach their ideal DTC and HCP audiences at crucial moments of their diagnosis and treatment journey. Using ML/AI and real world data, Swoop is a leader in developing brand-exclusive audiences of patients and their providers for healthcare companies. Once the right customers have been targeted, brands can drive bottom-of-the-funnel engagement through Swoop’s proprietary medically trained and MLR-compliant conversational AI. Built on a privacy-by-design foundation, Swoop is both HIPAA-certified and NAI accredited, having developed more than 12,000 unique target audiences for 42 of the top 50 pharmaceutical companies safely. Its conversational AI has been implemented across 100 health brands and trained on over 1.3 billion medical conversations.

Read More

Medical Devices

Medtronic Diabetes announces world's first approval for MiniMed™ 780G System with Simplera Sync™ disposable, all-in-one sensor

Medtronic | January 08, 2024

Medtronic plc a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors. The MiniMed 780G system with Simplera Sync™ sensor will be available in Europe via limited release in spring 2024. Medtronic will begin the phased commercial launch in Europe in the summer of 2024. Today, the MiniMed™ 780G system can be used with the Guardian™ 4 sensor. The MiniMed™ 780G system is Medtronic's most advanced insulin delivery system, automatically adjusting and correcting† glucose levels every 5 minutes.§ It's the world's only system with a Meal Detection™ feature‡ that is designed to reduce post-meal hyperglycemia when users occasionally forget to give themselves insulin or underestimate the number of carbs in their snacks or meal. The system, which is available with the world's only 7-day infusion set, also features one of the lowest glucose target settings (as low as 100 mg/dL) of any automated insulin delivery system. With this "treat to target" approach, the system more closely mirrors the glucose levels of someone not living with diabetes. With both Simplera Sync™ sensor and the Guardian™ 4 sensor, no fingersticks are required. "A challenging aspect of living with diabetes is counting carbohydrates and dosing the right amount of insulin before consuming snacks and meals. Many people underestimate their carbs, which can lead to high blood sugars (hyperglycemia). Prolonged hyperglycemia can lead to serious health problems impacting the eyes, major organs, and even cognitive function, which is particularly concerning in developing children," Robert Vigersky, M.D., Chief Medical Officer, Medtronic Diabetes, Professor of Medicine, Uniformed Services University of the Health Sciences "With its responsive algorithm, the MiniMed™ 780G system can help people living with diabetes even when they occasionally forget to bolus or undercount their carbs. The system takes on more of the work involved in diabetes management and helps alleviate mental burden." "We're incredibly proud that the MiniMed™ 780G system continues to be the most widely used automated insulin delivery system in Europe since we launched it in 2020. Real-world data on over 100,000 users on the system across many geographies and cultures shows that when using recommended settings the system is delivering an average Time in Range of nearly 80%, raising the bar on what 'good' looks like2," said Que Dallara, EVP and President, Medtronic Diabetes. "With the introduction of Simplera Sync™ sensor, we're able to offer the proven benefits of our MiniMed™ 780G system with our newest and most comfortable sensor that can be applied in under 10 seconds." The MiniMed™ 780G system with Simplera Sync™ sensor is indicated for ages 7+ and compatible with iOS and Android. Simplera Sync™ sensor is not approved by the FDA and is limited to investigational use in the U.S. Simplera Sync™ sensor is designed to leverage Medtronic's advanced AID algorithm as part of its MiniMed™ 780G system while having a similar look and feel as the Simplera™ CGM. The Simplera™ CGM for integrated use with the InPen™ smart insulin pen received CE Mark in September 2023. About the Diabetes Business at Medtronic Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Read More